UCT's Refine™ Ultra-Filtration technology allows for sample precipitation and filtration to occur simultaneously in the individual column/well. A novel, hydrophobically treated, submicron frit combination facilitates the removal of sample proteins without a complicated extraction.
Sample Extraction
a) Place a collection plate under the Refine™ Ultra-Filtration Plate.
b) Add 250 µL of urine and 250 µL Abalonase Ultra Enzyme working solution.
c) Hydrolyze for 30 min at 55 °C.
d) Further dilute sample by adding 500 µL D.I. H2O.
e) Mix sample. This can be executed via vortexing at maximum speed or multiple pipette aspirations and dispenses.
f) Filter the sample using one of the following techniques:
1. Centrifuge: For 5 min at 500 g or until filtrate is collected.
2. Vacuum: Apply vacuum at ~20" of Hg for up to 5 min or until filtrate is collected.
3. Positive Pressure: Apply 2–5 psi using positive pressure for up to 5 min or until filtrate is collected.
LC–MS/MS: Agilent™ 1200 HPLC and AB Sciex™ 4000 Q Trap (MS/MS)
Column: UCT Selectra® DA HPLC column 100 × 2.1 mm, 3 µm
Guard Column: UCT Selectra® DA guard column 10 × 2.1 mm, 3 µm
Injection volume: 10 µL
Mobile phase A: D.I. H2O + 0.1% formic acid
Mobile phase B: MeOH + 0.1% formic acid
Column flow rate: 0.30 mL/min
Table I: Percent reduction in analyte suppression following use of Refine™ plate compared to dilute and shoot preparation for hydrolyzed urine samples.
Using the above procedure, the Refine™ Ultra-Filtration technology allowed for a reduction in instrumental back pressure and removal of unwanted matrix components in urine samples. Overall, this allows for an end user to have enhanced analyte selectivity and an increase in HPLC/UPLC column life.
Figure 1: Back pressure per sample injection of Refine™ Ultra Filtration technology versus a dilute and shoot preparation for hydrolyzed urine samples.
UCT, LLC
2731 Bartram Rd, Bristol, PA 19007
tel: (800) 385-3153
Website:www.unitedchem.com
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.